Article Text

Download PDFPDF
The problem of pressure elevation associated with intravitreal triamcinolone
  1. M D Conway
  1. Correspondence to: Professor Mandi D Conway University of Arizona Health Sciences Center, Department of Ophthalmology and Vision Science, 655 N Alvernon Way, Suite 108, Tucson, AZ 85711, USA; mconway1{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

A question remains about the relation between the amount of drug in the vitreous cavity and the intraocular pressure elevation and duration

Intravitreal triamcinolone acetonide (IVTA) has increasingly been employed as a treatment for various intraocular inflammatory, neovascular, exudative, proliferative, and oedematous conditions.1–4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46 The injection usually results in transient improvement in visual acuity but repeated injections are usually required because the vision increases and eventually decreases again.8,9,10,19,21,43,45

Repeated IVTA injections have sparked investigations into the both dose response and quantification of the post-IVTA intraocular pressure rise.12,39,42,43 Although 4–8 mg doses drawn undiluted from the commercially available vial are commonly used, some investigators wash the diluent from the commercially available medication and concentrate it into a 20–25 mg dose in a small volume.10–12,16,21–24,39,40,42–46 In terms of the duration of the IVTA effect …

View Full Text

Linked Articles